CCA
INSM icon

Cravens & Co Advisors’s Insmed INSM Stock Holding History

Cravens & Co Advisors’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$330K Hold
2,020
– – 0.21% 55
2025
Q4 		$331K Hold
2,020
– – 0.22% 50
2025
Q3 		$291K Buy
+2,020
New +$247K 0.2% 50

Other funds holding INSM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cravens & Co Advisors's INSM Position: Q1 2026 in Review

Cravens & Co Advisors held its Insmed (INSM) position steady in Q1 2026 at 2,020 shares worth $330K. The position accounts for 0.21% of the portfolio, ranked #55.

Cravens & Co Advisors first reported a position in INSM in Q3 2025 and has held it in 3 quarters since. The position peaked at $331K in Q4 2025. 669 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

  • Cravens & Co Advisors held 2,020 shares of Insmed worth $330K as of Q1 2026.
  • Cravens & Co Advisors left its Insmed share count unchanged in Q1 2026.
  • Insmed made up 0.21% of Cravens & Co Advisors's portfolio in Q1 2026, its #55 holding.
  • Cravens & Co Advisors first reported a position in Insmed in Q3 2025 and has held it in 3 quarters since.
  • Cravens & Co Advisors's Insmed position peaked at $331K in Q4 2025.
  • 669 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on Cravens & Co Advisors's 13F filing for Q1 2026, filed 14 May 2026.